A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients with Generalized Myasthenia Gravis

March 23, 2021
https://clinicaltrials.gov/ct2/show/NCT04159805
Myasthenia Gravis
Principal Investigator: Kavita M Grover, MD
MG, Myasthenia Gravis
Open